Found: 43
Select item for more details and to access through your institution.
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
- Published in:
- Diabetic Medicine, 2014, v. 31, n. 12, p. 1505, doi. 10.1111/dme.12495
- By:
- Publication type:
- Article
Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
- Published in:
- Diabetic Medicine, 2011, v. 28, n. 11, p. 1352, doi. 10.1111/j.1464-5491.2011.03387.x
- By:
- Publication type:
- Article
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes T. Forst et al. Linagliptin added to metformin in Type 2 diabetes.
- Published in:
- Diabetic Medicine, 2010, v. 27, n. 12, p. 1409, doi. 10.1111/j.1464-5491.2010.03131.x
- By:
- Publication type:
- Article
Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.
- Published in:
- Diabetic Medicine, 2016, v. 33, n. 7, p. 926, doi. 10.1111/dme.13041
- By:
- Publication type:
- Article
Empagliflozin as add-on to metformin in people with Type 2 diabetes.
- Published in:
- Diabetic Medicine, 2015, v. 32, n. 12, p. 1555, doi. 10.1111/dme.12814
- By:
- Publication type:
- Article
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 10, p. 1034, doi. 10.1111/dom.12734
- By:
- Publication type:
- Article
Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 ( HSD1) inhibitor in humans: liver and adipose tissue 11β- HSD1 inhibition after acute and multiple administrations over 2 weeks.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 5, p. 483, doi. 10.1111/dom.12635
- By:
- Publication type:
- Article
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 12, p. 1180, doi. 10.1111/dom.12572
- By:
- Publication type:
- Article
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial ( EASE-1).
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 928, doi. 10.1111/dom.12494
- By:
- Publication type:
- Article
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 10, p. 936, doi. 10.1111/dom.12503
- By:
- Publication type:
- Article
Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 9, p. 868, doi. 10.1111/dom.12490
- By:
- Publication type:
- Article
Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 7, p. 699, doi. 10.1111/dom.12469
- By:
- Publication type:
- Article
Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 7, p. 665, doi. 10.1111/dom.12464
- By:
- Publication type:
- Article
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 3, p. 276, doi. 10.1111/dom.12419
- By:
- Publication type:
- Article
Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 2, p. 136, doi. 10.1111/dom.12399
- By:
- Publication type:
- Article
Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.
- Published in:
- Diabetes, Obesity & Metabolism, 2014, v. 16, n. 11, p. 1078, doi. 10.1111/dom.12321
- By:
- Publication type:
- Article
The dipeptidyl peptidase-4 inhibitor linagliptin lowers postprandial glucose and improves measures of β-cell function in type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2014, v. 16, n. 10, p. 1036, doi. 10.1111/dom.12312
- By:
- Publication type:
- Article
Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2014, v. 16, n. 6, p. 560, doi. 10.1111/dom.12281
- By:
- Publication type:
- Article
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2014, v. 16, n. 2, p. 147, doi. 10.1111/dom.12188
- By:
- Publication type:
- Article
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2) inhibitor, in subjects with renal impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2014, v. 16, n. 3, p. 215, doi. 10.1111/dom.12182
- By:
- Publication type:
- Article
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2014, v. 16, n. 2, p. 118, doi. 10.1111/dom.12183
- By:
- Publication type:
- Article
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
- Published in:
- Diabetes, Obesity & Metabolism, 2013, v. 15, n. 12, p. 1154, doi. 10.1111/dom.12185
- By:
- Publication type:
- Article
Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2013, v. 15, n. 9, p. 833, doi. 10.1111/dom.12110
- By:
- Publication type:
- Article
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2013, v. 15, n. 8, p. 721, doi. 10.1111/dom.12081
- By:
- Publication type:
- Article
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2013, v. 15, n. 7, p. 613, doi. 10.1111/dom.12073
- By:
- Publication type:
- Article
Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2013, v. 15, n. 4, p. 364, doi. 10.1111/dom.12039
- By:
- Publication type:
- Article
Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
- Published in:
- Diabetes, Obesity & Metabolism, 2013, v. 15, n. 4, p. 316, doi. 10.1111/dom.12028
- By:
- Publication type:
- Article
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
- Published in:
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 12, p. 1145, doi. 10.1111/dom.12011
- By:
- Publication type:
- Article
Response Letter to D. Singh-Franco et al.
- Published in:
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 11, p. 1054, doi. 10.1111/j.1463-1326.2012.01623.x
- By:
- Publication type:
- Article
Author response to letter from Snyder et al. regarding manuscript entitled 'Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor, linagliptin' by Graefe-Mody et al.
- Published in:
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 7, p. 671, doi. 10.1111/j.1463-1326.2012.01597.x
- By:
- Publication type:
- Article
Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.
- Published in:
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 6, p. 565, doi. 10.1111/j.1463-1326.2012.01590.x
- By:
- Publication type:
- Article
Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 5, p. 470, doi. 10.1111/j.1463-1326.2012.01565.x
- By:
- Publication type:
- Article
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
- Published in:
- Diabetes, Obesity & Metabolism, 2012, v. 14, n. 4, p. 348, doi. 10.1111/j.1463-1326.2011.01545.x
- By:
- Publication type:
- Article
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin.
- Published in:
- Diabetes, Obesity & Metabolism, 2011, v. 13, n. 10, p. 939, doi. 10.1111/j.1463-1326.2011.01458.x
- By:
- Publication type:
- Article
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
- Published in:
- Diabetes, Obesity & Metabolism, 2011, v. 13, n. 7, p. 653, doi. 10.1111/j.1463-1326.2011.01391.x
- By:
- Publication type:
- Article
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2011, v. 13, n. 3, p. 258, doi. 10.1111/j.1463-1326.2010.01350.x
- By:
- Publication type:
- Article
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
- Published in:
- Diabetes, Obesity & Metabolism, 2011, v. 13, n. 1, p. 65, doi. 10.1111/j.1463-1326.2010.01326.x
- By:
- Publication type:
- Article
Renal gluconeogenesis: its importance in human glucose homeostasis.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.
- Published in:
- International Journal of Clinical Practice, 2013, v. 67, n. 12, p. 1283, doi. 10.1111/ijcp.12308
- By:
- Publication type:
- Article
Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c <LT> 7% with no hypoglycaemia and no weight gain over 2 years.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA<sub>1c</sub> < 7% with no hypoglycaemia and no weight gain over 2 years.
- Published in:
- International Journal of Clinical Practice, 2013, v. 67, n. 4, p. 317, doi. 10.1111/ijcp.12101
- By:
- Publication type:
- Article
Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension.
- Published in:
- International Journal of Clinical Practice, 2012, v. 66, n. 8, p. 731, doi. 10.1111/j.1742-1241.2012.02975.x
- By:
- Publication type:
- Article
GLP-1 regulates gastroduodenal motility involving cholinergic pathways.
- Published in:
- Neurogastroenterology & Motility, 2009, v. 21, n. 6, p. 609, doi. 10.1111/j.1365-2982.2008.01246.x
- By:
- Publication type:
- Article